Shanghai Pharmaceutical announced that recently, sotalol hydrochloride tablets from its subsidiary Changzhou Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. The drug passed the consistent evaluation of the quality and efficacy of generic drugs. As of the date of this announcement, the company has invested about RMB 4.6 million in research and development for the consistency evaluation of this drug. According to the IQVIA database, the amount of sotalol hydrochloride tablets purchased by hospitals in mainland China in 2024 was RMB 33.117 million.

Shanghai Pharmaceutical announced that recently, sotalol hydrochloride tablets from its subsidiary Changzhou Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration. The drug passed the consistent evaluation of the quality and efficacy of generic drugs. As of the date of this announcement, the company has invested about RMB 4.6 million in research and development for the consistency evaluation of this drug. According to the IQVIA database, the amount of sotalol hydrochloride tablets purchased by hospitals in mainland China in 2024 was RMB 33.117 million.